GMR
The Original

BIOENGINEERED ARTIFICIAL KIDNEYS: ADVANCES IN TISSUE ENGINEERING AND ORGAN REGENERATION

Dr. Vinayak B Angadi[1], Dr. Abha Pandey[2], Dr. Nidhi Sachan[3], Dr. C. Ravichandran[4], Dr. Sonia Mor Chaudhary[5]

[1]Associate Professor, Department of Panchakarma, KLE Academy of Higher Education and Research, Shri B M Kankanawadi Ayurveda Mahavidyalaya, Shahapur, Belagavi 590003, Email ID: angadivinayak100@gmail.com, ORCID ID - 0000-0002-4730-8673
[2]Assistant Professor, Department of Life Sciences, School of Biosciences and Technology, Galgotias University, Greater Noida, Email ID: pandeyabhabhu@gmail.com ORCID ID: 0000-0001-5263-7271
[3]Assistant Professor, Department of Biomedical Sciences, School of Biosciences and Technology, Galgotias University, Greater Noida, Uttar Pradesh, India, Email ID: nidhi.sachan@galgotiasuniversity.edu.in, ORCID ID: 0009-0006-6585-9854
[4]Professor, Department of ECE, Tagore Institute of Engineering and Technology, Deviyakurichi, Salem D.T, PIN.636112, Email ID: ravisarvajith@gmail.com, ORCID ID: 0009-0009-8612-4402
[5]Assistant Professor, Clinical Research, Department of Biomedical Sciences, School of Biosciences and Technology, Galgotias University, Greater Noida, Email ID: sonia.mor@galgotiasuniversity.edu.in ORCID ID: 0000-0001-9182-2613

ABSTRACT

Chronic kidney disease (CKD) is a growing global health challenge, with end-stage renal disease (ESRD) imposing substantial morbidity, mortality, and socioeconomic burden. Current renal replacement therapies, dialysis and kidney transplantation, are limited by incomplete physiological replacement, reduced quality of life, and a persistent shortage of donor organs. These limitations have driven the development of bioengineered artificial kidneys as transformative alternatives. This review synthesises recent advances in bioengineered artificial kidneys, with a focus on tissue engineering, organ regeneration, and biohybrid device technologies, while critically examining translational barriers and future directions. We integrate findings from recent clinical, engineering, and regulatory literature to evaluate progress across key domains, including kidney structure-function constraints, cell sourcing strategies, biomaterials and scaffolding, nephron biofabrication, vascularisation and immune integration, and implantable versus extracorporeal systems. Preclinical validation, clinical translation, and regulatory considerations are also assessed. Significant progress has been made in stem cell-derived kidney organoids, decellularised extracellular matrix scaffolds, organ-on-chip platforms, and silicon-based filtration membranes. These technologies have enabled more physiologically relevant models of renal filtration and transport, improved vascularisation strategies, and early-stage implantable and wearable bioartificial kidney devices. While fully functional, transplantable bioengineered kidneys remain a long-term goal, hybrid and adjunctive technologies are approaching clinical feasibility. Continued interdisciplinary collaboration, coupled with advances in precision bioengineering, regulatory alignment, and scalable manufacturing, will be essential to translate artificial kidney technologies into meaningful clinical impact.

KEYWORDS: Bioengineered artificial kidney; Tissue engineering; Renal replacement therapy; Kidney organoids

1. INTRODUCTION

Chronic kidney disease (CKD) is a significant and increasing burden on health in the world, and its clinical, economic, and social effects are enormous. According to the latest calculations made by the Global Burden of Disease (GBD) Study 2023, CKD impacts hundreds of millions of adults worldwide and is steadily increasing in the majority of areas, owing to the ageing population, diabetes, hypertension, and health disparities [1]. In addition to being very prevalent, CKD is also linked with a high level of morbidity, premature death, and a poor quality of life, especially when the condition advances to end-stage renal disease (ESRD) wherein the functionality of the kidney is no longer adequate to support life without renal replacement therapy.

The existing modes of treatment of ESRD are mainly dialysis and kidney transplantation. Dialysis is indeed life-sustaining, but this is not a perfect replacement for native kidney functions. The traditional hemodialysis and peritoneal dialysis fail to fully replace the kidney with its continuous filtration and metabolic and endocrine functions, and such a replacement is associated with the development of cardiovascular problems, chronic inflammation, and severe limitations in lifestyle. This has led to significantly low quality of life and survival of patients under dialysis therapy compared to the general population [2]. Such limitations highlight the essence of the acute necessity of additional physiological and patient-centred approaches to renal replacement.

Kidney transplantation is the best intervention for ESRD and has better survival and quality-of-life results than dialysis. Transplantation is however, limited by the existing and increasingly growing gap between the supply and demand of organs. National and international registries have reported long transplant waiting lists and long waiting times consistently, and many patients die before a suitable organ becomes available [3,4]. Additionally, not all people will have access to transplantation because it is medically contraindicated, it is immunological, and healthcare infrastructure disparities.

Lifelong suppressions also pose risks of infection, malignancy, and graft failure, even in the case of transplant, which restricts long-term outcomes.

It is these clinical deficits that have spurred continued interest in substitute kidney replacement technologies that can address the shortcomings of dialysis and transplantation. During the last 20 years, progress in materials science, microfabrication, and cell biology has led to the idea of bioengineered artificial kidney systems, which should restore renal functions using wearable, implantable, or extracorporeal devices that are more closely related to natural kidney physiology. These technologies seek to offer continuous or semi-continuous renal support, enhance toxin clearance, and possibly reestablish metabolic and regulatory processes, unlike traditional dialysis that only does so intermittently [2].

The rate of technological innovation in this area has increased over the last few years due to the enhancement of membrane engineering, microfluidics, and the incorporation of living renal cells into biohybrid systems. In particular, wearable and implantable artificial kidney devices will help to fight the burden of treatment, increase patient mobility, and enhance hemodynamic stability through the use of continuous renal replacement [5]. Similar research in the extracorporeal bioartificial kidney attempts to enrich conventional dialysis with cell-based detoxification and metabolic assistance, offering an intermediate step towards more sophisticated renal replacement systems.

It is a challenge, nevertheless, to create clinically viable artificial kidneys. The kidney is among the most structurally and functionally complicated organs of the human body, which consists of millions of nephrons arranged in a dense vascular network and controlled by a complex of cellular and biochemical interactions. To recreate even a fraction of these functions, it would be necessary to have fine control of filtration, selective transport, fluid mechanics, and immune compatibility. This has led to the stagnation of a lot of promising technologies in the preclinical or early translational phase [2].

The increasing pressure on CKD throughout the world increases the need to innovate. It is estimated that CKD will keep rising up the ranks of the most serious causes of death in the world unless any breakthroughs are made in the sphere of prevention and treatment [1]. This trend leaves more pressure on health care platforms, especially in the low- and middle-income nations where dialysis and transplantation are not as accessible. Artificial kidney technologies that are scalable, durable, and affordable thus have a potential implication far beyond the lives of isolated patients, and into the health equity of the world at large.

Against this background, the timely undertaking of a critical assessment of bioengineered artificial kidney technologies is necessary. The purpose of this review is to synthesise the latest developments in tissue engineering, biomaterials, cell sourcing and device design that support the development of artificial kidneys. Through an overview of advances in all the implantable, wearable and extracorporeal systems, in addition to emphasising the biological, engineering and regulatory hurdles still to be overcome, this article would attempt to give a unified picture of the current and future potential of bioengineered kidney replacement therapies. Finally, to find the solution, artificial kidney technologies will necessitate interdisciplinary cooperation over time in order to fill the gap between experimental innovation and clinical reality, and the common objective of improving patient outcomes of kidney failure across the world.

2. Kidney Structure-Function Relationships: Design Constraints for Bioengineering

The kidney is a highly specialised organ, the capability to support systemic homeostasis of which comes out of the fact that structural, cellular, and biophysical properties are carefully integrated at a variety of spatial scales. Such structure-function interactions are useful to understand the real constraints of designing the kidney tissue engineering and bioartificial kidney development.

2.1 Macro- and Microanatomy of the Native Kidney

On a macroscopic scale, the kidney is differentiated into cortex and medulla that facilitates efficient countercurrent exchange and concentrates urine. On a microscopic level, this organisation facilitates a strictly controlled interaction between filtration, reabsorption and secretion, which is controlled by the local changes in oxygen tension, osmolarity and perfusion. The native kidney is highly anatomically complicated, which presents a considerable challenge to bioengineering methods that try to recapitulate the organ level [6].

2.2 Nephron Architecture and Functional Units

The nephron is the basic functional unit of the kidney, which consists of a glomerular filtration barrier with specialised tubular extensions involved in active solute and water reabsorption. There have been various transport mechanisms, metabolic needs, and structural variations between each segment of the nephron, and this fact highlights the challenge of recreating the nature of integrated nephron functionality in engineered environments [6].

2.3 Cellular Heterogeneity and Spatial Organisation

Renal activity requires the harmony of activity of various cell groups, such as podocytes, glomerular endothelial cells, mesangial cells, tubular epithelial subtypes, fibroblasts, and vascular cells. The podocytes have a key role to play in ensuring the integrity of the glomerular filtration barrier, and their interactions with endothelial and mesangial cells are essential to mechano-sensing and filtration selectivity [7,8]. Recent advances in kidney microenvironment atlases have highlighted the importance of spatially resolved cellular organisation in maintaining renal homeostasis and guiding tissue engineering strategies [9].

2.4 Mechanical, Biochemical, and Transport Requirements

Renal cells remain under dynamic mechanical forces such as shear stress due to filtrate flow, and cyclic strain due to capillary pressure. Besides that, the permeability, inflammation, and mechano-transduction are controlled by biochemical stimuli like the composition of the extracellular matrix and the integrity of the endothelial glycocalyx. The endothelial glycocalyx, specifically, is a key controller of vascular permeability and filtration barrier functionality, which is a design parameter that is frequently neglected in engineered renal systems [10].

2.5 Key Biological Challenges in Replicating Renal Physiology

To reproduce renal physiology, not only is it necessary to recreate cell types and in cellular culture, but also recreate the spatial organisation, biomechanical environment and interaction between cells. Interruption of crosstalk between podocytes, endothelial cells, and mesangial cells is a feature of kidney disease and demonstrates the instability of the renal filtration system [8]. These complexities underscore why engineered kidneys must move beyond simplified architectures toward biomimetic designs informed by detailed anatomical and cellular atlases [9]. The complex interplay between renal structure and function imposes stringent design constraints on bioengineered systems as shown in Table 1.

Table 1. Structural and Functional Design Constraints in Kidney Bioengineering

Kidney Feature	Native Function	Engineering Requirement	Key Challenge
Glomerular filtration barrier	Size- and charge-selective filtration	Nanoporous membranes, cell-cell interfaces	Protein leakage, thrombosis
Tubular epithelium	Selective reabsorption/secretion	Segment-specific transport modelling	Phenotypic stability
Vascular network	High perfusion, oxygen delivery	Perfusable microvasculature	Anastomosis, immune response
ECM microenvironment	Structural & biochemical signalling	Biomimetic scaffolds	Dynamic remodelling

3. Cell Sources for Artificial Kidney Engineering

The cellular source selection is one of the defining factors of functionality, scalability, and translational viability in artificial kidney engineering. The regeneration of renal tissue needs cellular populations that can reproduce the complexity of nephrons, extend the phenotypic stability over a long period of time, and blend their functionality with the host tissue. The existing approaches include primary renal cells and pluripotent stem cell-derived organoids, as well as approaches based on progenitors.

3.1 Primary Renal Cells

Primary renal cells, such as podocytes and tubular epithelial cells, have the benefit of having developed tissue-specific phenotypes and clearly defined functional characteristics. Their application allows modelling of renal physiology and drug response with a high level of accuracy, but with the disadvantages of being limited to expansion capacity and rapidly acquiring a phenotype during in vitro culture. Differentiation markers and functional loss persist as significant barriers and limit the scalability and long-term viability of primary cells as bioengineered kidney constructs [11]. Consequently, while primary renal cells are valuable for short-term functional studies, their limitations have driven the field toward stem cell-based alternatives.

3.2 Stem Cell-Derived Renal Lineages

Human pluripotent stem cells (hPSCs) have become a flexible and renewable source of renal cells. Recent protocols of directed differentiation have made it possible to generate populations of nephron progenitors and multicellular nephron-like kidney organoids capable of recapitulating the important features of nephron patterning and early kidney development. [12]. These organoids have segment-tube-like structures and glomerular-like compartments, which make them promising functional building blocks of artificial kidney systems.

Regardless of these developments, renal tissues derived from stem cells tend to exhibit undifferentiated phenotypes and inadequate structural coordination. Controlled extracellular matrix environments, mechanical stimulation, and vascularisation cues are also becoming a topic of bioengineering practises that can improve maturation and functional fidelity of organoids. [13]. Persistent challenges related to nephron connectivity, scale, and long-term stability continue to constrain their direct therapeutic application [14].

3.3 Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (iPSCs) have unique opportunities to be used in artificial kidney engineering because they can be cloned to autologous derivatives, and thus, their immunogenicity is reduced, and they have been applied in disease modelling and in personalised drug screening [11].

However, iPSC-based models have identical challenges to hPSC models, such as batch-to-batch differences, partial differentiation, and tumorigenicity. Before the iPSC-based renal tissues can be converted to an implantable or extracorporeal kidney replacement machine, a reproducible maturation and functional integration is also a key requisite [14].

3.4 Emerging Cell Sources

In addition to pluripotent stem cells, new approaches are underway as a way of tapping into transdifferentiation and endogenous renal progenitor populations. Direct lineage conversion methods are meant to produce renal epithelial or vascular cell types using somatic cells, which may be able to avoid the risks posed by pluripotency. Simultaneously, the discovery and maintenance of renal progenitor niches in organoid systems have been suggested as a way of improving tissue repair and plasticity [13].

The importance of developmental patterning and niche interactions to obtain higher-order renal architecture is emphasised by recent studies that incorporate collecting duct systems into kidney organoids [15]. These developments are indicative of a shift toward hybrid approaches involving the integration of stem cell biology with developmental and bioengineering concepts to address the existing constraints in artificial kidney cell source (Table 2).

Table 2. Cell Sources for Artificial Kidney Engineering: Advantages and Limitations

Cell Source	Advantages	Limitations	Translational Readiness
Primary renal cells	Mature phenotype	Limited expansion	Low
hPSC-derived cells	Scalability, diversity	Immaturity	Moderate
iPSC-derived cells	Autologous potential	Variability, cost	Moderate
Renal progenitors	Regenerative capacity	Poor definition	Early

4. Biomaterials and Scaffolding Strategies

The use of biomaterials and scaffolding approaches is also critical in artificial kidney engineering since they can offer structural, biochemical and mechanical stimuli that the renal cell requires to maintain survival, structure and functionality. Since the kidney has a complex extracellular matrix (ECM) structure and hierarchical design, scaffold construction needs to balance biocompatibility, bioactivity, and mechanical integrity, vascularisation, and tissue remodelling.

4.1 Natural Biomaterials

Collagen, gelatin, fibrin and decellularised extracellular matrix (dECM) are natural biomaterials that are commonly utilised in renal tissue engineering because of their inherent bio-compatibility and biochemical importance. These materials are very similar to the native renal microenvironment with cell adhesive motifs and signalling cues supporting renal cell attachment, differentiation, and functional maintenance. dECM-based kidney tissue-derived hydrogels maintain organ-biochemical composition, such as matrix proteins and remnants of growth factors, which can stimulate renal cell differentiation and tissue-like functions [16].

The bioactivity of natural biomaterials is specifically beneficial to support cell-ECM interactions that are essential to nephron development and repair. Still, their low mechanical strengths and batch-to-batch variations pose a problem to reproducibility and large-scale production, and require a high level of attention to material characterisation and processing.

4.2 Synthetic and Hybrid Biomaterials

The artificial polymers like polyethylene glycol (PEG), poly(lactic-co-glycolic acid) (PLGA) and polycaprolactone (PCL) provide accurate process control of mechanical qualities, degradation rate, and scaffold design. These materials allow one to design tunable systems that can survive physiological strains with the ability to regenerate tissues long-term. The objective of using hybrid biomaterials composed of synthetic backbones and natural components of the ECM is to incorporate the mechanical stability of synthetic polymers with the bioactivity of natural matrices.

Synthetic and hybrid scaffolds are being investigated in more renal operations to regulate mechano-transduction pathways and cell fate choices in response to stiffness gradients and degradation cues. This tunability is needed to reproduce the unique mechanical conditions experienced by the various nephron areas [17].

4.3 Decellularised Kidney Scaffolds

Whole-organ decellularisation has become an exciting approach to maintain the native kidney's three-dimensional structure and network of vascularity. Scaffolds in which the kidney has been decellularised preserve important components of the ECM, including microvascular channels, which offer a biologically relevant biocellularization platform to repassage renal and vascular cells [18]. The maintenance of vascular integrity is especially of high importance, where insufficient re-endothelialisation may result in thrombosis and poor perfusion.

The decellularised kidney scaffolds, despite their benefits, have major challenges regarding homogenous cell seeding, endothelialisation and integration of functions. The efficiency of recellularization is limited due to cell sourcing of the cells, spatial organisation, and repopulation of complex nephron structures. The potential and current shortcomings of regenerating functional kidneys using decellularised scaffolds and renal progenitor cells are also pointed out by studies that investigate the combination of these two methods [19].

4.4 Bioactive and Dynamic Scaffolds

In addition to structural support, newer renal scaffolds also include bioactive and dynamic characteristics in order to more closely replicate the renal microenvironment. Conditional provision of growth factors and angiogenic signals has been demonstrated to stimulate vascularisation and tissue maturation in decellularised and hybrid scaffolds [20]. Parallel to this, active scaffolds that can be dynamic in response to mechanical forces and cellular remodelling processes are being designed to facilitate long-term adaptation of tissues.

The role of matrix proteins in mechano-transduction and ECM remodelling in kidney injury and regeneration has been key in regulating cell behaviour via integrin signalling and cytoskeletal arrangement [17]. The integration of these principles in scaffold design is an important milestone in designing biomimetic renal structures that can be used in vivo to function over time and integrate. The various scaffold types have varying strengths and weaknesses in the use of renal tissue engineering (Table 3).

Table 3. Biomaterials and Scaffolding Strategies for Renal Tissue Engineering

Scaffold Type	Key Materials	Advantages	Major Limitations
Natural biomaterials	Collagen, fibrin	Bioactivity	Weak mechanics
Synthetic polymers	PEG, PLGA, PCL	Tunable properties	Low bioactivity
Hybrid scaffolds	Polymer + ECM	Balanced properties	Complex fabrication
dECM scaffolds	Whole kidney ECM	Native architecture	Recellularization

5. Engineering Functional Renal Units

Development of operative renal modules is a vital milestone in the quest for bioartificial kidneys that can simulate indigenous functions of filtration, reabsorption, and secretion. This has necessitated the exact combination of glomerular and tubular elements, as well as physiologically viable transport processes and changing mechanical signals that regulate renal activity in vivo. Functional renal unit engineering needs an orchestrated effort at cellular, material, and fluidic levels, as shown in Figure 1.



Figure 1. Multiscale engineering of functional renal units

5.1 Nephron Biofabrication

Nephron biofabrication is a process to recapitulate the structural and functional complexity of the tubular and glomerular compartments, which are collectively comprised of the nephron. The glomerular filtration barrier is a specialised structure that is sensitive to mechanical forces, consisting of podocytes, endothelial cells, and basement membrane, making it especially challenging. Pressure-controlled filtration and mechanical stress have also shown to trigger podocyte differentiation and functional maturation, so biomechanical cues should be included in engineered nephron systems [21]. In addition to glomerular modelling, selective transport processes along the tubular channels should be faithfully recapitulated in order to develop physiologically relevant solute transport. Compartmentalised culture systems, engineered renal microtissues are used to study the dynamics of transport at the nephron level and disease dysfunction in both therapeutic development and mechanistic studies [22].

5.2 Microfluidic and Organ-on-Chip Systems

Microfluidic and organ-on-chip systems have been identified as potent systems used in simulating kidney processes based on controlled and reproducible conditions. Kidney-on-a-chip devices allow physiologically relevant shear stress and flow dynamics to be applied, and it is possible to study in real time mechano-transduction, filtration, and responses to drugs. These systems provide the interface between the non-dynamic in vitro cultures and in vivo physiology, with better predictive ability of nephrotoxicity and disease modelling [23,24].

Microfluidic devices that embrace the concept of co-culture also improve physiological relevance by facilitating cell-cell interactions that are required in the maintenance of filtration barriers. Multicellular models that include glomerular endothelial cells and podocytes have been shown to have better barrier properties and stability in phenotype over monocultures, and the significance of multicellular organisation of engineered renal units has been demonstrated [25].

5.3 3D Bioprinting Technologies

Three-dimensional bioprinting provides a flexible method in the spatial organisation of renal cell types across complicated structures that mimic native nephron morphology. Extrusion-based, inkjet, and laser-assisted bioprinting methods allow the deposition of cells and biomaterials in control, making it possible to create layered glomerular and tubular structures. These approaches enable accurate spatial sorting of renal cells and enable the creation of sophisticated in vitro disease model systems and drug discovery systems [22].

Nevertheless, the present bioprinting technologies have drawbacks in the form of resolution, scalability, and functional stability over time. Recreating the capillary level characteristics and the incorporation of perfusable vasculature networks are still problems in translating bioprinted renal units into bioartificial kidney systems that are clinically relevant. Further improvements in bioink formulation, printing resolution and dynamic culture conditions are needed to surpass these obstacles and allow nephron fabrication at scale [23,24].

6. Vascularisation and Immune Integration

The development of workable vascular systems and successful immune compatibility is one of the greatest bottlenecks in the clinical translation of bioengineered kidney tissues. Because of the incredibly large perfusion requirements of the kidney and immunological tolerance of the organ, effective kidney renal tissue engineering should resolve the lack of vascularisation that is perfusable and regulation of the host immune response.

6.1 Importance of Perfusable Vascular Networks

Oxygen and nutrient delivery, waste elimination, and long-term functionality of created renal tissues require perfusable vascular networks. In normal kidneys, there is an extensive system of capillaries that assist in filling the metabolic needs of the nephron sections and process filtration and reabsorption. Hypoxia, necrosis and functional deterioration within engineered systems caused by inadequate vascularisation inhibit the maturation and scalability of tissues. Recent research points to the fact that vascularisation is not just a supportive property but a precondition to organoid growth, maturation, and functional stability [26,27].

6.2 Angiogenic Strategies and Endothelialisation

Several methods have been studied to induce angiogenesis and endothelialisation of renal constructs, which include endothelial cells, angiogenic stem cells, and pro-vascular biomaterials. Decellularised kidney scaffolds can maintain original vascular channels, which serve as a structural basis of re-endothelialisation and perfusion. Angiogenic cell population methods of recellularization have been shown to have increased vascular integration and perfusion capacity in bioengineered kidney models [28].

Microfluidic platforms also make it possible to induce angiogenesis in controlled conditions reproducing physiological flow conditions and thus real-time monitoring of the vascular development. The fact that xenotransplantation of embryonic kidney tissue into microfluidic systems can sustain vascular invasion and maturation highlights the importance of dynamic flow and mechanical cues in vascular maturation [29].

6.3 Host Integration and Anastomosis

To enable engineered renal tissues to work in vivo, novel vascular networks have to be able to anastomose effectively with the host circulatory system. Integration of the engineered and host vasculature, endothelial compatibility and the maintenance of the extracellular matrix architecture are required to achieve successful host integration. Improved integration results with scaffold and Organoid systems with guided vascular patterning in place imply that pre-vascularisation approaches can increase engraftment activity and functional survival [26,27].

6.4 Immune Response, Inflammation, and Rejection Risks

The implanted renal constructs present a lot of challenges in regard to immune recognition and inflammatory responses. Both biomaterials and cellular components may induce the immune activation process, resulting in fibrosis, thrombosis, or graft rejection. Poor endothelialisation only increases these dangers by revealing thrombus-generating surfaces and facilitating inflammatory responses. The immunological implications of being able to understand the vascular and matrix composition are thus essential in reducing adverse host responses [30].

6.5 Immunomodulatory Biomaterials and Cell Engineering

Emerging strategies aim to address immune rejection by using immunomodulatory biomaterials and engineered cell populations. A change in scaffold composition to incorporate ECM elements that suppress inflammatory signalling, or the design of cells with lower immunogenicity, is a promising approach to enhance graft tolerance. It is suggested that the structural and biochemical characteristics of the extracellular matrix are central in the regulation of immune cell behaviour and mechano-transduction, which makes matrix-informed design especially vital in vascularized renal models [30].

7. Implantable Bioartificial Kidneys vs. Extracorporeal Systems

Bioartificial kidney technology has taken two major translational directions in its development, namely implantable/wearable systems aimed at providing continuous renal replacement and extracorporeal systems aimed to augment or replace traditional dialysis. Both methods represent various engineering interests, clinical limitations, and patient-centred factors.

7.1 Wearable and Implantable Devices

Implantable and wearable bioartificial kidney designs will offer continuous renal therapy and limit the reliance of patients on traditional dialysis systems. Key to most designs of implants are silicon-based nanopore membranes and hemofilter technologies that allow a selective ultrafiltration process, whilst maintaining hemocompatibility. These membranes provide good control of pore size and transport characteristics, which enable clearance of uremic toxins and reduced protein loss [31].

Hybrid biological-synthetic systems are an important technological development in this area, which involves engineered filtration membranes and living renal cells placed in bioreactors. The aim of such designs is to restore filtration, metabolic and endocrine functions of the kidney. Evidence-based trials have indicated that implantable renal bioreactors that can sustain cell viability and functionality in vivo are possible, which has provided evidence as to their potential in long-term implantation [31]. However, issues pertaining to immune protection, thrombosis prophylaxis and durability at long term still constitute major impediments to any clinical translation [32].

7.2 Extracorporeal Bioartificial Kidneys

Extracorporeal bioartificial kidney systems are based on existing dialysis systems, which are enhanced with biological components to increase the levels of detoxification and metabolic support. These systems usually use renal epithelial cells in bioreactors to undergo active transport, metabolism conversion and immunomodulatory roles that could not be achieved using conventional dialysis alone. Their extracorporeal design enables them to be monitored, serviced and replaced easily, thus alleviating some of the dangers of permanent implantation [33].

Extracorporeal systems have been subjected to clinical assessment based on safety, toxin removability, and short-term clinical results. Although these platforms have shown encouraging performance as primary criteria in preclinical and initial clinical systems, their dependence on external circuitry and intermittent therapy restricts their capacity to completely recreate endogenous native kidney functions [5]. Consequently, extracorporeal bioartificial kidneys have been considered as transitional technologies and not permanent long-term solutions.

7.3 Comparative Analysis

Considering the functional approach, continuous renal replacement, hemodynamic stability, and increased mobility of the patient are the hypothetical benefits of an implantable bioartificial kidney. These advantages, however, are offset by heightened technical complexity, surgical risk and biocompatibility and immune protection demands [32,33]. Conversely, the extracorporeal systems are more controllable and safer in the early development stages, but come at a significant lifetime cost burden, and their quality-of-life benefits can be minimal over fully implantable devices [5].

Finally, the decision between implantable and extracorporeal bioartificial kidney systems is indicative of a trade-off between the functional ambition and translational feasibility. Further developments in membrane engineering, cell sourcing and immunomodulation will be very important in dictating which method or combination of methods will come out as the most viable clinical solution to end-stage kidney disease [33,34]. Key differences between implantable and extracorporeal bioartificial kidney systems are summarised in Table 4.

Table 4. Comparison of Implantable and Extracorporeal Bioartificial Kidney Systems

Feature	Implantable Systems	Extracorporeal Systems
Mode of operation	Continuous	Intermittent
Patient mobility	High	Limited
Surgical requirement	Yes	No
Immune risk	Higher	Lower
Clinical maturity	Early	Moderate

8. Preclinical and Clinical Progress

To translate bioartificial kidney technologies into clinical reality, it is essential to ensure their rigorous preclinical validation, translational milestones with clear objectives, and to avoid taking regulatory pathways. The movement in this area has been gradual, influenced by the improvement in technology as well as the experience of previous clinical endeavours.

8.1 Animal Models and Functional Validation

Animal models have played a major role in preclinical testing of bioartificial kidney systems due to their ability to test their biocompatibility, filtration, hemodynamic stability, and immunologic reactions. There is proof-of-concept evidence in small and large animal models, which have been used to demonstrate cell-based renal support, microfluidic kidney models and hybrid bioengineered devices. Such experiments present the necessary information about the security of the device, the functional stability and host reactions, which then guide further design improvements [35].

Kidney-on-a-chip systems have also become complementary preclinical models, which allow high-resolution functional studies and mechanistic research in controlled settings. This kind of systems enables quick iteration and screening before in vivo testing, and translational risk is minimised, and resource drainage is lowered [23].

8.2 Translational Milestones

The major milestones in the field of bioartificial kidney development are the ability to maintain the renal cell functions, filtration membranes, hemocompatibility, and scalable production procedures. The development of wearable and implantable devices engineering has helped bring additional clinical impetus, enhanced by the supply of better materials, microfabrication and cell sourcing methods [35].

In spite of these developments, translation has been hampered by issues to prolonged stability of devices, immune compatibility and regulatory complexity. The history of artificial kidney highlights the need to focus on balancing technological aspiration, clinical feasibility and patient outcomes [36].

8.3 Current Clinical Trials and Regulatory Status

Bioartificial kidney technologies have very little clinical assessment, but it is slowly increasing. The current experiments, including the trials testing the renal assist devices, show that the development of these devices proceeds carefully, and the priority is put on the safety, feasibility, and short-term functionality results [37]. Regulatory control focuses on risk reduction, device dependability and the expression of clinical advantage prior to a wider application.

Wearable dialysis devices also achieved significant regulatory milestones, such as pre-pivotal trial completion and designation pathways that will help to speed up the development. Those innovations are indicators of growing regulatory interest in novel renal replacement technologies, though the data on long-term clinical effectiveness is yet to be obtained [38].

8.4 Lessons Learned from Failed or Stalled Approaches

The history of failures and halting of programmes in developing artificial kidneys gives invaluable information in the endeavours that are underway, as well as in the future. Major challenges are a lack of functional integration, unexpected immune or inflammatory reactions, and challenges in maintaining long-term functionality in the presence of physiological conditions. There were situations where clinical preparedness could not keep up with technological complexity, which resulted in premature translation attempts [36].

Taken together, these experiences demonstrate the necessity of rigorous preclinical validation, achievable performance standards, and strategies of iterative development. Combining the lessons that have been learned in the first failures with the new technologies and regulatory standards, the sphere is getting closer to the development of clinically viable bioartificial kidney solutions [35].

9. Regulatory, Manufacturing, and Ethical Considerations

The biotechnical application of bioengineered artificial kidneys is dictated by the scientific and technical feasibility, as well as high regulatory, production, and ethical standards. Artificial kidneys as hybrid systems of biological, cellular and device-based components present special challenges that cannot be reduced to conventional medical devices or cell therapies.

9.1 GMP-Compliant Manufacturing Challenges

Adherence to Good Manufacturing Practise (GMP) is a cornerstone to the clinical application of cell-based and biohybrid technologies of kidney replacement. The issues of manufacturing are also especially acute when it comes to systems that involve pluripotent stem cell-derived renal cells, whereby batch-to-batch consistency, risk of contamination, and phenotypic instability have to be kept under stringent control. Manufacture of therapeutic cell products derived from iPSC will require an effective quality control, standardised differentiation procedures, and scalable bioprocessing systems to achieve safety, efficacy and reproducibility [39].

In the case of bioartificial kidneys, compliance with GMP should run through biological as well as device parts, such as sourcing cells, manufacturing the scaffold, and assembling the devices. Having these processes in a single manufacturing line is a significant logistical and regulatory challenge.

9.2 Standardisation and Scalability

To transform bioengineered kidney technologies into commercially viable and deployable products, standardisation is needed to transition these technologies into products rather than specialised laboratory models. The absence of standardised methods to characterise cells, functional performance measures and long-term stability makes cross-studies comparison and regulatory assessment difficult. These difficulties are further increased by the concept of scalability since processes at a small scale might not work effectively when scaled to manufacturing production at clinical scales.

The introduction of uniform potency, safety and functional equivalence assays will be the key to regulatory acceptance and commercial feasibility. Such factors are especially pertinent with regard to the combination products, where the variability in one part can lead to undermining of the performance of the entire system [40].

9.3 Regulatory Pathways

The bioartificial kidneys are commonly categorised as combination products, and this includes biologics, medical devices, and, in some instances, advanced therapy medicinal products. Regulatory oversight thus comes with the coordination of the assessment of various regulatory frameworks. The Food and Drug Administration (FDA) in the United States has guidance on combination products that includes the primary mode of action, risk-based assessment, and inter-rater cooperation in the course of the evaluation [41].

The resources of regulatory knowledge provide insight into the difficulty in navigating approval routes to such products, especially where biological and mechanical functions are closely coupled together [42]. Prior interaction with regulators is slowly becoming a necessity to ensure product development is regulator-friendly and not held up in the clinical translation process.

9.4 Ethical Considerations

Ethical issues of bioengineered artificial kidneys are sourcing and manipulation of stem cells, application of genetic engineering to improve functionality or immune compatibility, and fair access to superior treatments. Although iPSC technologies alleviate certain ethical issues that come with embryonic stem cells, they raise new issues related to genetic modification, long-term safety, and informed consent [39].

In addition to the ethical concerns of the field of science, the issue of access and affordability is crucial in the overall impact of artificial kidney technologies on society. Unless there are conscious endeavours to combat cost, scalability, and healthcare infrastructure disparity, then there is a possibility that these innovations will further increase the inequity in the treatment of kidney disease. Ethical and regulatory frameworks should thus keep up with the pace of technological change so as to have responsible and inclusive implementation [40].

10. Future Directions and Emerging Paradigms

The bioengineered artificial kidneys field is moving out of demonstration proof-of-concept systems to more advanced, interconnected systems. The prospects of the future will lie in the synthesis of developments in computational design and synthetic biology, regenerative medicine, and customised healthcare, and in realistic evaluations of translation schedules. Existing and novel translational approaches to bioengineered artificial kidneys are illustrated in Figure 2.



Figure 2. Translational pathways and future trajectories of bioengineered artificial kidneys

10.1 AI-Guided Kidney Design and Biofabrication

Machine learning and artificial intelligence (AI) can significantly transform kidney bioengineering by allowing the use of data-driven design of kidney tissues and devices. Such AI-driven models can incorporate massive data sets of renal anatomy, cellular behaviour, fluid flows, and material behaviour to optimise the scaffold designs, organisation of nephrons, and their transport efficiency. The AI-based control systems can be used in biofabrication processes to achieve

more reproducibility and precision in bioprinting, microfluidics, and organoid differentiation processes, by dynamically controlling parameters in response to real-time feedback.
In addition to fabrication, a predictive model using AI can be used to promise acceleration of preclinical testing by modelling the workings of devices, cellular maturation and long-term functional stability. These methods would make the process of experimental iteration manyfold shorter and make the translational process much more efficient.

10.2 Gene Editing and Synthetic Biology Integration

The technology of gene editing, especially CRISPR-based systems, provides fresh possibilities to achieve better functionality, safety and durability of bioengineered kidney constructs. Increased resistance to hypoxia, immune recognition, transport, and metabolic functions might be strengthened by genetic modification of renal cells. Simultaneously, synthetic biology methods allow the design of programmable cellular functions, e.g. regulated secretion of growth factors, active adaptation to mechanical stimuli, or self-regulated metabolic states.
Taking gene-edited cells into bioartificial kidneys suggests both relevant regulatory and ethical concerns and offers a potent toolkit to address the regulations and restrictions related to cell maturity, immune rejection, and performance in the long-term aspect.

10.3 Toward Fully Functional Whole-Organ Regeneration

Kidney bioengineering is aimed at the eventual production of fully functional transplantable organs that can substitute native kidneys in end-stage disease. This will necessitate concerted developments in various areas, such as scalable nephron generation, hierarchical vascularisation, innervation and a smooth host integration. Whole-organ decellularisation-recellularization methods, advanced bioprinting, and fusion of organoids represent alternative directions of this goal.
Even with these great advances, it is still not possible to reproduce the complete complexity of renal physiology with endocrine functions, precise solute processing, and long-term adjustment. Newer attempts will probably involve hybrid approaches of combining partial organ regeneration with implantable or extracorporeal support apparatus instead of trying to regenerate whole organs at once.

10.4 Personalised and Precision Renal Bioengineering

Personalised medicine is one of the major new paradigms in the development of artificial kidneys. The combination of patient-specific renal cells derived using iPSC with customised scaffold and device designs will allow tailoring of renal replacement therapies to personal genetic, metabolic, and immunological profiles. This kind of accuracy would enhance the effectiveness of any therapeutic process, decrease positive immune reactions, and allow modelling of diseases and testing drugs on an individual basis.
Nonetheless, the concept of personalisation also brings more complexity in terms of the manufacturing process, regulatory certification, and manufacturing costs. The key to realising the precision renal bioengineering within the general clinical practise, instead of the specialised applications, will be balancing between individualised design and scalable production.

10.5 Timeline to Clinical Reality

Although the first steps in the incremental clinical development are already being implemented, the development of fully implantable bioengineered kidneys will continue to be a long-term goal. The future of progress is probably in hybrid and adjunctive technologies, including wearable technology, extracorporeal bioartificial kidneys, and partial regenerative therapy in the near term. The medium-term goals are better durability, better vascularization and stronger immune incorporation of implantable systems.
The interdisciplinary collaboration and regulatory involvement over a long period, which may include decades, are likely to be needed to fully function and transplant bioengineered kidneys. However, with the fast rate of innovation in the fields of bioengineering, computational biology and regenerative medicine, it is anticipated that the role of artificial kidney technologies in the management of kidney disease will grow progressively central to the process in the future.

11. CONCLUSIONS

The development of bioengineered artificial kidneys is a fast-moving area of renal replacement therapy that has been necessitated by the clinical imperative to overcome the shortcomings of dialysis and organ transplantation. Advances in stem cell biology, biomaterials science, microfluidic engineering, and biofabrication have facilitated more advanced models of renal structure and function that have drawn the field nearer to clinically relevant solutions. The development of kidney organoids, decellularised scaffolds, and organ-on-chip microphysical environments has increased the mechanistic insights and offered viable platforms on which therapeutic development can be tested. Although such accomplishments have been made, there are major challenges that have to be addressed. Mimicking the complexity of the nephron architecture, the achievement of long-term vascularisation and immune compatibility remain limiting to long-term functionality and translational success. There are also manufacturing, regulatory and ethical factors to consider, especially when dealing with combination products, which are a combination of living cells and synthetic devices. In order to tackle these challenges, coordinated actions will be necessary in terms of standardisation of the performance metrics, scaling of GMP-compliant manufacturing, and aligning the technological innovation with regulatory expectations. In future, artificial intelligence, gene editing, and precision bioengineering are converging to provide transformative opportunities for speeding up design and improving functionality and personalising renal replacement therapies. Although fully implantable, transplantable bioengineered kidneys are a long-term ambition, hybrid and

adjunctive technology is likely to provide significant clinical benefit in the near to medium term. To bring these innovations to the bedside, further interdisciplinary efforts between engineers, biologists, clinicians and regulators will be needed. All of these advances are a positive sign that indicates the change of paradigm in kidney disease management and makes bioengineered artificial kidneys one of the pillars of further kidney therapy.

REFERENCES

[1]Mark PB, Stafford LK, Grams ME, Aalruz H, Abd ElHafeez S, Abdelgalil AA, et al. Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet 2025;406:2461–82.

[2] Groth T, Stegmayr BG, Ash SR, Kuchinka J, Wieringa FP, Fissell WH, et al. Wearable and implantable artificial kidney devices for end-stage kidney disease treatment: Current status and review. Artificial Organs 2023;47:649–66.

[3] Chronic kidney disease: Australian facts, Kidney transplantation. Australian Institute of Health and Welfare 2024. https://www.aihw.gov.au/reports/chronic-kidney-disease/chronic-kidney-disease/contents/treatment-and-management-of-chronic-kidney-disease/kidney-transplantation?utm_source=chatgpt.com (accessed December 30, 2025).

[4] Padilla S. International Registry in Organ Donation and Transplantation 2024.

[5] Wieringa FP, Suran S, Søndergaard H, Ash S, Cummins C, Chaudhuri AR, et al. The Future of Technology-Based Kidney Replacement Therapies: An Update on Portable, Wearable, and Implantable Artificial Kidneys. American Journal of Kidney Diseases 2025.

[6] Kingston J, Khan S, Moinuddin Z. Function of the nephron and the formation of urine. Anaesthesia & Intensive Care Medicine 2024;25:339–43.

[7] Cunanan J, Zhang D, Peired AJ, Barua M. Podocytes in health and glomerular disease. Frontiers in Cell and Developmental Biology 2025;13:1564847.

[8] Hu S, Hang X, Wei Y, Wang H, Zhang L, Zhao L. Crosstalk among podocytes, glomerular endothelial cells and mesangial cells in diabetic kidney disease: an updated review. Cell Commun Signal 2024;22:136.

[9] Koldenhof J, Verhaar MC, Masereeuw R, Slaats GG, van Genderen AM. How a kidney microenvironment atlas can advance kidney tissue engineering. Trends in Biotechnology 2025.

[10] Yuan X, Jia M, Zhou L, Hou G, Zhang B, Ouyang X, et al. The Endothelial Glycocalyx: The First Line of Defense in the Prevention and Treatment of Kidney Diseases. Kidney Medicine 2025:101122.

[11] Xi Y, Song W. Kidney organoids in translational research: disease modeling, drug discovery, and unresolved challenges. Cell Tissue Res 2025;402:303–12. https://doi.org/10.1007/s00441-025-04018-5.

[12] Kim H-Y, Yu S, Choi YJ, Gee HY. Kidney organoids: development and applications. Organoid 2023;3.

[13] Corredera IG, Amato G, Moya-Rull D, Garreta E, Montserrat N. Unlocking the full potential of human pluripotent stem cell derived kidney organoids through bioengineering. Kidney International 2025.

[14] van den Berg CW, Dumas SJ, Little MH, Rabelink TJ. Challenges in maturation and integration of kidney organoids for stem cell–based renal replacement therapy. Kidney International 2025;107:262–70.

[15] Shi M, Crouse B, Sundaram N, Shakked NP, Thorner K, King NM, et al. Integrating collecting systems in human kidney organoids through fusion of distal nephron to ureteric bud. Cell Stem Cell 2025.

[16] Quinteira R, Gimondi S, Monteiro NO, Sobreiro-Almeida R, Lasagni L, Romagnani P, et al. Decellularized kidney extracellular matrix-based hydrogels for renal tissue engineering. Acta Biomaterialia 2024;180:295–307.

[17] Lin P-H, Duann P. Matrix Proteins in Kidney Injury, Fibrosis, and Regeneration. In: Das H, editor. Tissue Repair and Regeneration, Cham: Springer Nature Switzerland; 2025, p. 49–71. https://doi.org/10.1007/978-3-031-93677-7_3.

[18] Khazaei MR, Ibrahim R, Faris R, Bozorgi A, Khazaei M, Rezakhani L. Decellularized kidney capsule as a three-dimensional scaffold for tissue regeneration. Cell Tissue Bank 2024;25:721–34. https://doi.org/10.1007/s10561-024-10136-1.

[19] Hsu C-Y, Chi P-L, Chen H-Y, Ou S-H, Chou K-J, Fang H-C, et al. Kidney bioengineering by using decellularized kidney scaffold and renal progenitor cells. Tissue and Cell 2022;74:101699.

[20] Mazloomnejad R, Babajani A, Kasravi M, Ahmadi A, Shariatzadeh S, Bahrami S, et al. Angiogenesis and Re-endothelialization in decellularized scaffolds: Recent advances and current challenges in tissue engineering. Frontiers in Bioengineering and Biotechnology 2023;11:1103727.

[21] Doi K, Kimura H, Kim SH, Kaneda S, Wada T, Tanaka T, et al. Enhanced podocyte differentiation and changing drug toxicity sensitivity through pressure-controlled mechanical filtration stress on a glomerulus-on-a-chip. Lab on a Chip 2023;23:437–50.

[22] Buttó S, Vidal S, Zeng XR, Rausch M, Yasa IC, Ferro MP. Engineered 3D Kidney Glomerular Microtissues to Model Podocyte-Centric Diseases for the Validation of New Drug Targets. Adv Healthcare Materials 2025;14:2404767. https://doi.org/10.1002/adhm.202404767.

[23] Nishimura Y. Revolutionizing renal research: The future of kidney-on-a-chip in biotechnology. Regenerative Therapy 2024;26:275–80.

[24] Huang W, Chen Y-Y, He F-F, Zhang C. Revolutionizing nephrology research: expanding horizons with kidney-on-a-chip and beyond. Frontiers in Bioengineering and Biotechnology 2024;12:1373386.

[25] ‘t Hart DC, Yildiz D, Palacio-Castañeda V, Li L, Gumuscu B, Brock R, et al. Co-culture of glomerular endothelial cells and podocytes in a custom-designed glomerulus-on-a-chip model improves the filtration barrier integrity and affects the glomerular cell phenotype. Biosensors 2023;13:339.

[26] Raykhel I, Nishikawa M, Sakai Y, Vainio SJ, Skovorodkin I. Vascularization of kidney organoids: different strategies and perspectives. Frontiers in Urology 2024;4:1355042.

[27] Cuenca MV, Bulut M, Mummery CL, Orlova VV. Vascularization of organoid microenvironments: Perfusable networks for organoid growth and maturation. Current Opinion in Biomedical Engineering 2025;34:100586.
[28] Liu H, Wen X, Shi Y, Zhou Y, Chen X, Song W, et al. Vascularized Bioengineered Kidney Using Decellularized Scaffold Recellularized with human Placenta-Derived Angiogenic stem Cells and Kidney Organoids. bioRxiv 2025:2025–07.
[29] Oliveira M, Sarker PP, Skovorodkin I, Kalantarifard A, Haskavuk T, Mac Intyre J, et al. From ex ovo to in vitro: xenotransplantation and vascularization of mouse embryonic kidneys in a microfluidic chip. Lab on a Chip 2024;24:4816–26.
[30] Lacueva-Aparicio A, Lindoso RS, Mihăilă SM, Giménez I. Role of extracellular matrix components and structure in new renal models in vitro. Frontiers in Physiology 2022;13:1048738.
[31] Kim EJ, Chen C, Gologorsky R, Santandreu A, Torres A, Wright N, et al. Feasibility of an implantable bioreactor for renal cell therapy using silicon nanopore membranes. Nature Communications 2023;14:4890.
[32] Nalesso F, Garzotto F, Cattarin L, Bettin E, Cacciapuoti M, Silvestre C, et al. The future for end-stage kidney disease treatment: Implantable bioartificial kidney challenge. Applied Sciences 2024;14:491.
[33] Ramada DL, de Vries J, Vollenbroek J, Noor N, Ter Beek O, Mihăilă SM, et al. Portable, wearable and implantable artificial kidney systems: needs, opportunities and challenges. Nature Reviews Nephrology 2023;19:481–90.
[34] Seddik A, Alalawi F. Implantable Bioartificial Kidney, Review of Literature 2023.
[35] Huang B, Zeng Z, Zhang CC, Schreiber ME, Li Z. Approaches to kidney replacement therapies—opportunities and challenges. Frontiers in Cell and Developmental Biology 2022;10:953408.
[36] Blum K. Researchers Hope to Move Ahead with Artificial Kidney 2020.
[37] 3ive Labs. Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes. clinicaltrials.gov; 2025.
[38] Vivance's Viva Kompact Completes Pre-Pivotal Trial of Wearable Dialysis Device | Vivance n.d. https://vivance.com/vivance-completes-pre-pivotal-trial-of-wearable-dialysis-device/?utm_source=chatgpt.com (accessed December 30, 2025).
[39] Haase A, Ruhparwar A, Martin U. GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations. Advanced Drug Delivery Reviews 2025:115744.
[40] Tian J, Song X, Wang Y, Cheng M, Lu S, Xu W, et al. Regulatory perspectives of combination products. Bioactive Materials 2022;10:492–503.
[41] Commissioner O of the. Guidance & Regulatory Information. FDA 2024. https://www.fda.gov/combination-products/guidance-regulatory-information (accessed December 30, 2025).
[42] Reinert C. Regulatory Knowledge Guide for Combination Products 2023.